Vaccine Virtual Days health professional sitting with stethoscope around neck

Vaccine Virtual Days 2022

March 30th & 31st

Let science guide the way

Vaccine Virtual Days are coming March 30th & 31st 2022. This event will be a unique opportunity to connect with the broader vaccine community with a focus on adult immunisation.

The value and importance of adult immunisation has been discussed globally over the last 12 months. Now is the time to come together as a community of healthcare professionals, interested in adult immunisation, to hear the latest science and data on vaccine technologies, barriers to immunisation, including vaccine confidence and much more.

Vaccine Virtual Days friendly smiling young doctor talking and explaining test result to elderly patient in hospital

Register now

Your opportunity to connect with the global vaccine community and hear latest news and findings on adult immunisation.

REGISTER NOW

This year’s event will cover the following agenda topics:

community

The need for life-course vaccination programs and the impact of immunosenescence in adults

target

Immunisation of the most vulnerable: What’s the current situation?

leaflet

Challenges and opportunities for implementation of adult vaccination and policies

globe

New players in the world of adult immunisation: Who are they and what’s their impact?

vaccine

Vaccine technologies and future challenges: What does the science tell us?

conversation

Role of vaccine confidence in adult immunisation and influence of social media

goal

Learnings from the COVID-19 pandemic

question mark

Ask the expert!

The agenda topics have been selected by an independent Scientific Committee of international experts

Jane Barrat

CANADA

Jane Barratt

Secretary General, International Federation on Ageing Member, Vision Academy, Director, Baycrest Health Sciences, CSO Rep. WHO COVAX Pillar vaccine strategy

Paolo Bonnani

Italy

Paolo Bonanni

Professor of Hygiene and Public Health Sciences, Director of the Department of Health Sciences, University of Florence

Stefania Maggi

Italy

Stefania Maggi

Director of research c/o National Research Council, Neuroscience Institute-Aging Branch Padua, Italy

Jean-Pierre Michel

Switzerland

Jean-Pierre Michel

Professor of Geriatric Medicine and Honorary professor of Medicine, Geneva University – Switzerland, Member of the French and Spanish Academy of Medicine 

John Oppenheimer

USA

John Oppenheimer

Director of Clinical Research at Pulmonary and Allergy Associates, Clinical Professor of Medicine at UMDNJ-Rutgers

Rosana Richtmann

Brazil

Rosana Richtmann

Infectious Disease Physician from Emílio Ribas Institute, Director of the Immunization Committee from the Brazilian Society of Infectious Disease, PhD by Freiburg University, Germany

Mich Rothholz

USA

Mitchel Rothholz

Chief of Governance & State Affiliates and Executive Director, APhA Foundation, American Pharmacists Association

Mary Slack

UK

Mary Slack

Independent Consultant at Mary Slack Microbiology Consulting Ltd, Professor at Griffith University School of Medicine, Australia

LJ Tan

USA

LJ Tan

Chief Strategy Officer, Immunize.org, Co-Chair, National Adult and Influenza Immunization Summit

Vaccine Virtual Days Hand doctor's working using pen writing on medical prescription

Ask the expert

Submit your questions to be addressed at the “Ask the expert” session hosted by the independent Scientific Committee.

SUBMIT YOUR QUESTIONS

Five great reasons to register for Vaccine Virtual Days 2022 

lecture

Unique opportunity to learn from leading experts from across the globe

community

Engagement with broader vaccine community

tablet

Interactive sessions with international experts

conversations

Live & OnDemand available in 8 languages

certificate

Certificate of Attendance available per session

Downloadable Agenda

Discover more information about the Vaccine Virtual Days 2022 agenda and speakers.

Vaccine Virtual Days guiding lines

Vaccine Virtual Days 2022

Let science guide the way
March 30th & 31st

Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

LOCs to insert local adverse events reporting procedure.

© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.

NX-GBL-GVX-WCNT-210013 | January 2022